ORAL ETOPOSIDE IN COMBINATION WITH FARNESYLTRANSFERASE INHIBITOR R115777

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The outcome and survival for adults age 70 and older with AML remains poor. Part of this poor response relates to the inability of very elderly patients (age > 75) to tolerate intensive chemotherapy [13-17]. More important, however, is the inherent resistance of these AMLs to the cytotoxic effects of traditional cytotoxic agents [14,17]. The AMLs that arise in the older age group often do so from an antecedent hematologic disorder (mainly MDS) that itself has evolve from a background of toxin exposures. These MDS/AMLS exhibit a complex genetic profile, likely a result of cumulative genomic damage .